Arcus Biosciences Inc (RCUS) Company Profile & Statistics

Arcus Biosciences Inc
RCUS
(NYSE)
Open
14.72
-0.98 (-6.24%)
in:usd•As of: Nov 18, 2024 13:28 UTC -5
Open
15.49
High
15.58
Low
14.72

About Arcus Biosciences Inc

CEO

Terry Rosen

Headquarters

3928 point eden way

hayward, ca 94545, united states

Auditor

Ernst & Young LLP

Employees

577

Share Holders

Website

www.arcusbio.com

Industry

biotechnology

Sector

health technology

Company Overview

Arcus Biosciences is a biopharmaceutical company. It focused on creating innovative cancer immunotherapies. The company's product portfolio includes AB928, AB122, AB154 and AB680. AB928 which is in its final phase is a potent and selective dual antagonist of the adenosine receptors. AB122 which is in its Phase1 is a monoclonal antibody which potently and selectively blocks a protein called PD-1. AB154 is a monoclonal antibody which potently and selectively blocks a novel immune checkpoint called TIGIT. AB680, which is in its Phase1 is a potent and selective inhibitor of CD73, the enzyme responsible for the extracellular production of adenosine within the tumor micro-environment. Arcus Biosciences is based in Hayward, CA.

Arcus Biosciences Inc Statistics

Valuation Measures

Market Capitalization ²	1.35B
Enterprise Value	1.19B
Enterprise Value/EBITDA (ttm)	-3.58
Price to Earnings Ratio (ttm)	N/A
Price to Book (mrq)	2.54
Price to Sales (ttm)	5.46
Price to Cash (ytd)	N/A

Profitability

Gross Margin (ttm)	100.00%
Operating Margin (ttm)	-102.66%
Profit Margin (ttm)	-173.54%
Return on Equity (ttm)	-45.59%
Return on Invested Capital (ttm)	-47.78%
Return on Assets (ttm)	-22.38%

Income Statement

Revenue (ttm)	263.00M
Revenue Per Share (ttm)	2.87
Gross Profit (ttm)	263.00M
EBITDA (ttm)³	-333.00M
Net Income Avi to Common (ttm)	-270.00M
Diluted EPS (ttm)	-3.15

Share Statistics

Beta (5Y Monthly)	0.89
52-Week Change	5.44%
S&P500 52-Week Change	29.71%
S&P500 Member	No
Stock Optionable	Yes
Total Shares Outstanding ¹	91.51M
Dividend Yield	0.00%
Float ⁴	80.26M
% Held by Insiders	12.30%
% Held by Institutions	92.89%

Balance Sheet

Total Cash (mrq)	1.09B
Total Cash Per Share (mrq)	11.90
Total Debt (mrq)	47.00M
Total Debt/Equity (mrq)	8.32%
Current Ratio (mrq)	5.24%
Quick Ratio (mrq)	5.24%
Book Value Per Share (mrq)	6.17

Cash Flow

Operating Cash Flow Per Share (ytd)	-0.77
Free Cash Flow (ytd)	-75.00M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. Stock price provided by Xignite. All numbers are rounded to the closest decimal.

¹ Total Shares outstanding is taken from the most recently filed quarterly or annual report.

² Market Cap is calculated using total shares outstanding and the most recent share price.

³ EBITDA is calculated using methodology that may differ from that used by a company in its reporting.

⁴ The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

Arcus Biosciences Inc

Trade With A Regulated Broker